COVARIS is open to selected conversations with sponsors, CROs, clinical development teams, trial operations leaders and scientific collaborators.

A first conversation is most relevant if you are working with late phase 2 or phase 3 planning and want to understand whether planned countries, regions or enrollment windows introduce disease-relevant environmental instability before protocol lock.

Useful context to include:

• indication or disease area
• development stage
• planned countries or regions
• expected enrollment or assessment window
• relevant endpoint context